Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction

Experimental Neurology

Volumn 221, Issue 1, 2010, Pages 217-224

  Costa, Cinzia ^a,b   Tozzi, Alessandro ^a,b   Luchetti, Elisa ^a,b   Siliquini, Sabrina ^a,b   Belcastro, Vincenzo ^a,b   Tantucci, Michela ^a,b   Picconi, Barbara ^b   Ientile, Riccardo ^c   Calabresi, Paolo ^a,b   Pisani, Francesco ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Electrophysiology; GABA; Neuroprotection; Parkinson's disease; Rotenone; Striatum; Zonisamide

Indexed keywords

3 NITROPROPIONIC ACID; 4 AMINOBUTYRIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; SUCCINATE DEHYDROGENASE (UBIQUINONE); ZONISAMIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN ISCHEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; EVOKED CORTICAL RESPONSE; EXCITATORY POSTSYNAPTIC POTENTIAL; HUNTINGTON CHOREA; IN VITRO STUDY; MOLECULAR MECHANICS; NERVE CELL EXCITABILITY; NERVE CELL MEMBRANE STEADY POTENTIAL; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT;

ACTION POTENTIALS; ANIMALS; ANTIOXIDANTS; BICUCULLINE; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXCITATORY POSTSYNAPTIC POTENTIALS; GABA ANTAGONISTS; GLUCOSE; GLUTAMIC ACID; ISOXAZOLES; MALE; NEURONS; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, WISTAR; ROTENONE; UNCOUPLING AGENTS;

EID: 72749097853     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.11.002     Document Type: Article

References (85)

1. Albers D.S., and Beal M.F. Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem. Int. 40 (2002) 559-564
2. Albers D.S., Swerdlow R.H., Manfredi G., Gajewski C., Yang L., Parker W.D., and Beal M.F. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp. Neurol. 168 (2002) 196-198
3. 2 elevation, not ATP depletion. J. Neurosci. 25 (2005) 10029-10040
4. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?. Ann. Neurol. 31 (1992) 119-130
5. Beal M.F. Role of excitotoxicity in human neurological disease. Curr. Opin. Neurobiol. 2 (1992) 657-662
6. Beal M.F. Mitochondrial dysfunction in neurodegenerative diseases. Biochim. Biophys. Acta 10 (1998) 211-223
7. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., and Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13 (1993) 4181-4192
8. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
9. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin. Neuropharmacol. 30 (2007) 230-240
10. Bonsi P., Calabresi P., De Persis C., Papa M., Centonze D., Bernardi G., and Pisani A. Early ionic and membrane potential changes caused by the pesticide rotenone in striatal cholinergic interneurons. Exp. Neurol. 185 (2004) 169-181
11. Brouillet E., Conde F., Beal M.F., and Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59 (1999) 427-468
12. Brouillet E., and Hantraye P. Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Curr. Opin. Neurol. 8 (1995) 469-473
13. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M.K., Bird E.D., and Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41 (1997) 646-653
14. Büeler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp. Neurol. 218 (2009) 235-246
15. Calabresi P., De Murtas M., Stefani A., Pisani A., Sancesario G., Mercuri N.B., and Bernardi G. Action of GP47779, the active metabolite of oxcarbazepine, on corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 36 (1995) 990-996
16. Calabresi P., Pisani A., Mercuri N.B., and Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 19 (1996) 19-24
17. Calabresi P., Centonze D., Pisani A., and Bernardi G. Endogenous adenosine mediates the presynaptic inhibition induced by aglycemia at corticostriatal synapses. J. Neurosci. 17 (1997) 4509-4516
18. Calabresi P., Centonze D., Pisani A., Sancesario G., Gubellini P., Marfia G.A., and Bernardi G. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann. Neurol. 43 (1998) 586-597
19. Calabresi P., Centonze D., Marfia G.A., Pisani A., and Bernardi G. An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. Br. J. Pharmacol. 126 (1999) 689-696
20. Calabresi P., Centonze D., and Bernardi G. Cellular factors controlling neuronal vulnerability in the brain: a lesson from the striatum. Neurology 14 (2000) 1249-1255
21. Calabresi P., Centonze D., Gubellini P., Marfia G.A., Pisani A., Sancesario G., and Bernardi G. Synaptic transmission in the striatum: from plasticity to neurodegeneration. Prog. Neurobiol. 61 (2000) 231-265
22. Calabresi P., Picconi B., Saulle E., Centonze D., Hainsworth A.H., and Bernardi G. Is pharmacological neuroprotection dependent on reduced glutamate release. Stroke 31 (2000) 766-772
23. Calabresi P., Gubellini P., Picconi B., Centonze D., Pisani A., Bonsi P., Greengard P., Hipskind R.A., Borrelli E., and Bernardi G. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J. Neurosci. 21 (2001) 5110-5120
24. Calabresi P., Cupini L.M., Centonze D., Pisani F., and Bernardi G. Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann. Neurol. 53 (2003) 693-702
25. Calabresi P., Picconi B., Tozzi A., and Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 30 (2007) 211-219
26. Centonze D., Prosperetti C., Barone I., Rossi S., Picconi B., Tscherter A., De Chiara V., Bernardi G., and Calabresi P. NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitroproprionic acid but not of rotenone in the striatum. Exp. Neurology 202 (2006) 470-479
27. Champy P., Höglinger G.U., Feger J., Gleye C., Hocquemiller R., Laurens A., Guerineau V., Laprevote O., Medja F., Lombes A., Michel P.P., Lannuzel A., Hirsch E.C., and Ruberg M. Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J. Neurochem. 88 (2004) 63-69
28. Chase T.N., and Oh J.D. Striatal dopamine-and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23 (2000) S86-91
29. Chirichigno J.W., Manfredi G., Beal M.F., and Albers D.S. Stress-induced mitochondrial depolarization and oxidative damage in PSP cybrids. Brain Res. 951 (2002) 31-35
30. Costa C., Leone G., Saulle E., Pisani F., Bernardi G., and Calabresi P. Coactivation of GABA(A) and GABA(B) receptor results in neuroprotection during in vitro ischemia. Stroke 35 (2004) 596-600
31. Costa C., Martella G., Picconi B., Prosperetti C., Pisani A., Di Filippo M., Pisani F., Bernardi G., and Calabresi P. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 37 (2006) 1319-1326
32. Costa C., Belcastro V., Tozzi A., Di Filippo M., Tantucci M., Siliquini S., Autuori A., Picconi B., Spillantini M.G., Fedele E., Pittaluga A., Raiteri M., and Calabresi P. Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J. Neurosci. 28 (2008) 8040-8052
33. Di Filippo M., Picconi B., Costa C., Bagetta V., Tantucci M., Parnetti L., and Calabresi P. Pathways of neurodegeneration and experimental models of basal ganglia disorders: downstream effects of mitochondrial inhibition. Eur. J. Pharmacol. 545 (2006) 65-72
34. Dong X.X., Wang Y., and Qin Z.H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 30 (2009) 379-387
35. Ferrante R.J., Schulz J.B., Kowall N.W., and Beal F.M. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res. 753 (1997) 157-162
36. Foehring R.C., Mermelstein P.G., Song W.J., Ulrich S., and Surmeier D.J. Unique properties of R-type calcium currents in neocortical and neostriatal neurons. J. Neurophysiol. 84 (2000) 2225-2236
37. Granger P., Biton B., Faure C., Vige X., Depoortere H., Graham D., Langer S.Z., Scatton B., and Avenet P. Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol. Pharmacol. 47 (1995) 1189-1196
38. Greene J.G., and Greenamyre J.T. Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol. 48 (1996) 613-634
39. Hayakawa T., Higuchi Y., Nigami H., and Hattori H. Zonisamide reduces hypoxic-ischemic brain damage in neonatal rats irrespective of its anticonvulsive effect. Eur. J. Pharmacol. 257 (1994) 131-136
40. He Y., Imam S.Z., Dong Z., Jankovic J., Ali S.F., Appel S.H., and Le W. Role of nitric oxide in rotenone-induced nigro-striatal injury. J. Neurochem. 86 (2003) 1338-1345
41. Höglinger G.U., Féger J., Prigent A., Michel P.P., Parain K., Champy P., Ruberg M., Oerte W.H., and Hirsch E.C. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84 (2003) 491-502
42. Kanki R., Nakamizo T., Yamashita H., Kihara T., Sawada H., Uemura K., Kawamata J., Shibasaki H., Akaike A., and Shimohama S. Effects of mitochondrial dysfunction on glutamate receptor-mediated neurotoxicity in cultured rat spinal motor neurons. Brain Res. 1015 (2004) 73-81
43. 2+mobilization in rat hippocampus. Epilepsy Res. 35 (1999) 173-182
44. Kim G.W., Copin J.C., Kawase M., Chen S.F., Sato S., Gobbel G.T., and Chan P.H. Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin, 3-nitropropionic acid. J. Cereb. Blood Flow Metab. 20 (2000) 119-129
45. Kito M., Maehara M., and Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 5 (1996) 115-119
46. Komatsu M., Okamura Y., and Hiramatsu M. Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats. Neurosciences 21 (1995) 23-29
47. Komatsu M., Hiramatsu M., and Willmore L.J. Zonisamide reduces the increase in 8-hydroxy-2 deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats. Epilepsia 41 (2000) 1091-1094
48. Lee W.T., Itoh T., and Pleasure D. Acute and chronic alterations in calcium homeostasis in 3-nitropropionic acid-treated human NT2-N neurons. Neuroscience 113 (2002) 699-708
49. Luetjens C.M., Bui N.T., Sengpiel B., Münstermann G., Poppe M., Krohn A.J., Bauerbach E., Krieglstein J., and Prehn J.H. Delayed mitochondrial dysfunction in excitotoxic neuron death: cytochrome c release and a secondary increase in superoxide production. J. Neurosci. 20 (2000) 5715-5723
50. Manabe T., Wyllie D.J.I., and Nicoll R.A. Modulation of synaptic transmission and long-term potentiation: effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. J. Neurophysiol. 70 (1993) 1451-1459
51. Matar N., Jin W., Wrubel H., Hescheler J., Schneider T., and Weiergräber M. Zonisamide block of cloned human T-type voltage-gated calcium channels. Epilepsy Res. 83 (2009) 224-234
52. Masuda Y., Utsui Y., Shiraishi Y., Karasawa T., Yoshida K., and Shimuzu M. Relationship between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals. Epilepsia 20 (1979) 623-633
53. Mattson M.P., Gleichmann M., and Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 60 (2008) 748-766
54. McLean M.J., and Macdonald R.L. Carbamazepine and 10,11-epoxycarbamazepine produce use-and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 238 (1986) 727-737
55. McLean M.J., and Macdonald R.L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 237 (1986) 1001-1011
56. Mimaki T., Suzuki Y., Tagawa T., and Yabuuchi H. Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med. J. Osaka Univ. 39 (1990) 13-17
57. Minato H., Kikuta C., Fujitani B., and Masuda Y. Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats. Epilepsia 38 (1997) 975-980
58. Mori A., Noda Y., and Packer L. The anticonvulsivant zonisamide scavenger free radicals. Epilepsy Res. 30 (1998) 153-158
59. Murata M., Hasegawa K., and Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68 (2007) 45-50
60. 2+dependent dopamine release. Epilepsy Res. 13 (1992) 113-119
61. Okada M., Kaneko S., Hirano T., Mizuno K., Kondo T., Otani K., and Fukushima Y. Effects of zonisamide on dopaminergic system. Epilepsy Res. 22 (1995) 193-205
62. Okada M., Kawata Y., Mizuno K., Wada K., Kondo T., and Kaneko S. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with amicrodialysis electrode. Br. J. Pharmacol. 124 (1998) 1277-1285
63. Okada M., Zhu G., Yoshida S., Kanai K., Hirose S., and Kaneko S. Exocytosis mechanism as a new targeting site for mechanisms of action of antiepileptic drugs. Life Sci. 72 (2002) 465-473
64. Owen A.J., Ijaz S., Miyashita H., Wishart T., Howlett W., and Shuaib A. Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioral study. Brain Res. 770 (1997) 115-122
65. Patsalos P.N., Berry D.J., Bourgeois B.F., Cloyd J.C., Glauser T.A., Johannessen S.I., Leppik I.E., Tomson T., and Perucca E. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49 (2008) 1239-1276
66. Picconi B., Centonze D., Håkansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., and Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 6 (2003) 501-506
67. Pisani A., Bonsi P., and Calabresi P. Calcium signaling and neuronal vulnerability to ischemia in the striatum. Cell. Calcium 36 (2004) 277-284
68. 2+rise induced by oxygen/glucose deprivation in cortical neurons. Stroke 29 (1998) 196-201
69. Rock D.M., Macdonald R.L., and Taylor C.P. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 3 (1989) 138-143
70. Rogawski M.A., and Loescher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5 (2004) 553-564
71. Schapira A.H., Gu M., Taanman J.W., Tabrizi S.J., Seaton T., Cleeter M., and Cooper J.M. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol. 44 (1998) S89-98
72. Schauf C.L. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res. 413 (1987) 185-188
73. Sherer T.B., Richardson J.R., Testa C.M., Seo B.B., Panov A.V., Yagi T., Matsuno-Yagi A., Miller G.W., and Greenamyre J.T. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J. Neurochem. 100 (2007) 1469-1479
74. Schulz P.E., Cook E.P., and Johnston D. Changes in paired-pulse facilitation suggest presynaptic involvement in long-term potentiation. J. Neurosci. 14 (1994) 5325-5337
75. Sobieszek G., Borowicz K.K., Kimber-Trojnar Z., Małek R., Piskorska B., and Czuczwar S.J. Zonisamide: a new antiepileptic drug. Pol. J. Pharmacol. 55 (2003) 683-689
76. Striano S., Striano P., Capone D., and Pisani F. Limited place for plasma monitoring of new antiepileptic drugs in clinical practice. Med. Sci. Monit. 14 (2008) 73-78
77. Suzuki S., Kawakami K., Nishimura S., Watanabe Y., Yagi K., Seino M., and Miyamoto K. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 12 (1992) 21-27
78. Swerdlow R.H., Golbe L.I., Parks J.K., Cassarino D.S., Binder D.R., Grawey A.E., Litvan I., Bennett J.P., Wooten G.F., and Parker W.D. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J. Neurochem. 75 (2000) 1681-1684
79. Thöne J., Leniger T., Splettstösser F., and Wiemann M. Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition. Epilepsy Res. 79 (2008) 105-111
80. Tozzi A., Costa C., Di Filippo M., Tantucci M., Siliquini S., Belcastro V., Parnetti L., Picconi B., and Calabresi P. Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid. Exp. Neurol. 207 (2007) 218-226
81. Ueda Y., Doi T., Tokumaru J., Nakajima A., and Nagatomo K. In vivo evaluation of the effect of zonisamide on the hippocampal redox state during kainic acid-induced seizure status in rats. Neurochem. Res. 30 (2005) 1117-1121
82. Yano R., Yokoyama H., Kuroiwa H., Kato H., and Araki T. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice. J. Mol. Neurosci. 39 (2009) 211-219
83. Yaari Y., Seltzer M., and Pincus J. Phenytoin: mechanism of its anticonvulsivant action. Ann. Neurol. 20 (1986) 171-184
84. Yoshida S., Okada M., Zhu G., and Kaneko S. Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors. Epilepsy Res. 67 (2005) 153-162
85. Zhu C., Vourc'h P., Fernagut P.O., Fleming S.M., Lacan S., Dicarlo C.D., Seaman R.L., and Chesselet M.F. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J. Comp. Neurol. 478 (2004) 418-426